Tissue Collection for Biomarkers Determining Resistance to Ibrutinib

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

NCT02682641 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

NCT01599949 ·Status: COMPLETED ·Phase: PHASE2

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

NCT06572618 ·Status: RECRUITING ·Phase: PHASE2

Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment

NCT01521689 ·Status: UNKNOWN ·Phase: PHASE2

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT01833039 ·Status: APPROVED_FOR_MARKETING

A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

NCT05506410 ·Status: RECRUITING

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

NCT00126191 ·Status: TERMINATED ·Phase: PHASE2

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

NCT04876092 ·Status: COMPLETED ·Phase: PHASE1

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT04994626 ·Status: UNKNOWN ·Phase: PHASE2

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

NCT02867566 ·Status: COMPLETED ·Phase: PHASE3

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT02427620 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

NCT02272686 ·Status: TERMINATED ·Phase: PHASE2

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT03581942 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults

NCT01809600 ·Status: COMPLETED

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

NCT00053092 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

NCT03282396 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

NCT07099443 ·Status: RECRUITING

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01880567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

NCT00429065 ·Status: UNKNOWN

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

NCT01980654 ·Status: COMPLETED ·Phase: PHASE2

Ublituximab + Ibrutinib in Select B-cell Malignancies

NCT02013128 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma

NCT01446562 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

NCT00133991 ·Status: COMPLETED ·Phase: PHASE2

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma

NCT01766583 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970 ·Status: COMPLETED ·Phase: PHASE2